8.41  0.35 (4.34%)		04-30 16:00
Open: 8.09 High: 8.64 Volume: 327,999		Pre. Close: 8.06 Low: 8 Market Cap: 673(M)

Short term
Mid term
Targets	6-month :	10.55	1-year :	11.3
Resists	First :	9.03	Second :	9.68
Pivot price	8.92
Supports	First :	8	Second :	6.65
MAs	MA(5) :	8.56	MA(20) :	8.88
	MA(100) :	10.65	MA(250) :	10.86
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	22.9	D(3) :	32.2
RSI	RSI(14): 41.5
52-week	High :	14.86	Low :	8

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BBOT ] has closed above bottom band by 17.0%. Bollinger Bands are 26.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	8.65 - 8.69	8.69 - 8.73
Low:	7.9 - 7.94	7.94 - 7.99
Close:	8.33 - 8.41	8.41 - 8.48

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Thu, 30 Apr 2026
BBOT (NASDAQ: BBOT) registers 63.05M common shares for resale - Stock Titan

Thu, 30 Apr 2026
BridgeBio Oncology (NASDAQ: BBOT) accounting chief reports initial equity stake - Stock Titan

Thu, 30 Apr 2026
BridgeBio Oncology (NASDAQ: BBOT) COO Idan details initial stock and option holdings - Stock Titan

Thu, 30 Apr 2026
BBOT SEC Filings - BridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Tue, 28 Apr 2026
[ARS] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan

Mon, 27 Apr 2026
Latest BBOT News - BBOT Presents Preclinical Data Demonstratin... - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	80 (M)
Shares Float	31 (M)
Held by Insiders	27.2 (%)
Held by Institutions	70.3 (%)
Shares Short	2,260 (K)
Shares Short P.Month	2,330 (K)

EPS	-4.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.13
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29.8 %
Return on Equity (ttm)	-48.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.82
Qtrly Earnings Growth	0 %
Operating Cash Flow	-114 (M)
Levered Free Cash Flow	-74 (M)

PE Ratio	-1.96
PEG Ratio	0
Price to Book value	1.63
Price to Sales	0
Price to Cash Flow	-5.91

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.